Public BoD papers 28.04.22

Agenda Item 17/22a

Meeting of the Board of Directors Thursday 28 th April 2022

Board Assurance Framework 2021/22

1

Introduction The board assurance framework (BAF) 2021/22 was presented to the Board of Directors and Quality Assurance Committee in March and Audit Committee in February. Further review of the board assurance framework has taken place by the executive team and company secretary since the meeting. Updates to the risks Minor updates have been made to the assurance and gaps in control sections relating to some of the risks. Risk scores have been assessed at the end of the financial year for all risks and the end of Q4 scores have been added for each risk. A column has also been added that shows whether the risk is rolling over into the BAF 2022/23. In line with an action from the last Board meeting the following risk was reassessed and the risk score increased; 5.4 The Christie Pharmacy Company objectives not achieved impacting on clinical service, patient experience and Trust reputation – risk score increased to reflect departmental risks (6 to 12).

2

3

Suggested updates There are no other suggested updates to the risks identified in the Board Assurance Framework at year-end, the closing position of the 2021/22 framework.

4

Recommendation To note the year-end position of the Board Assurance Framework (BAF) 2021/22 that reflects the risks to achievement of the corporate objectives.

94